ArticleBioinformation2025
Immunohistochemistry as a diagnostic tool in pathology.
Article in Bioinformation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunohistochemistry (IHC) is an important tool in pathology and allows visualization of antigens when obtaining tissue specimens from patients and employs labeled antibodies directed against those antigens. IHC is helpful to improve tumor classification, identify pathogens and discover prognostic markers when distinguishing features are absent or minimized by morphological assessment. As routine IHC has emerged over the years, monoclonal antibodies and further development of automated stainers allow for increased sensitivity and specificity of antigens assessed by IHC. Since cancer classification relies upon IHC to subtype cancers, define the origin of metastases and to administer targeted therapy, IHC remains a valuable and necessary process for clinical pathology. Innovations continue to be made in IHC, such as new biomarkers, multiplexing and fluorescent technology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.